Seven Travere Therapeutics Insiders Sell $6.5M in TVTX Stock — CEO Dube Leads at $5M

All seven Travere Therapeutics C-suite executives sold TVTX stock in early 2026, with CEO Eric M. Dube leading at $5.04 million across 4 transactions. The total: $6.51 million from the CEO, CFO, CMO, CCO, CRO, CLO, and CAO — a rare clean sweep of the executive suite.

The Full C-Suite Sold

Insider	Title	Value	Shares After	Career Sales
Eric M. Dube	Chief Executive Officer	$5.04M	419,173	$14.0M
William E. Rote	Chief Research Officer	$410K	109,087	$4.7M
Peter Heerma	Chief Commercial Officer	$230K	131,823	$1.6M
Elizabeth E. Reed	Chief Legal Officer & GC	$230K	108,205	$2.5M
Christopher R. Cline	Chief Financial Officer	$230K	112,971	$1.3M
Jula Inrig	Chief Medical Officer	$220K	107,485	$1.2M
Sandra Calvin	SVP, Chief Accounting Officer	$140K	49,080	$5.1M
Total: 7 insiders		$6.51M

CEO Dube: $14M Career, 77% of the Selling

Eric Dube sold $5.04M — representing 77% of all insider proceeds. His 4 transactions and $14M career total make him the dominant seller. He retains 419,173 shares, a meaningful position, but his career sales are now roughly 2.5x the value of his remaining holdings.

Why 7 of 7 Matters

Travere Therapeutics develops therapies for rare kidney and liver diseases. The company has Filspari (sparsentan) on the market and a pipeline focused on rare metabolic conditions.

When all seven C-suite executives sell simultaneously, it's almost certainly a coordinated 10b5-1 plan execution. The non-CEO sellers all sold relatively similar amounts ($140K - $410K), suggesting pre-set percentage-based selling across the group.

But the coordination mechanism doesn't negate the message. These seven executives collectively chose to set up selling plans at current price levels, and all seven triggered at the same time:

• CEO (sold): $5.04M — largest block by far
• CRO (sold): $410K — research leadership monetizing
• CCO (sold): $230K — commercial leadership monetizing
• CLO (sold): $230K — legal counsel monetizing
• CFO (sold): $230K — the person who sees the numbers first
• CMO (sold): $220K — the person who runs clinical trials
• CAO (sold): $140K — smallest, but still participating

Career Context

Combined career sales across all seven insiders total $30.4 million. For a mid-cap biotech with a market cap around $4 billion, this cumulative insider monetization is meaningful.

CAO Sandra Calvin stands out with $5.1M in career sales — the second-highest among this group despite her lower current-round selling. Calvin has been a steady seller over time, and her long-term pattern adds weight to the overall picture.

For TVTX investors, the 100% C-suite participation rate is the signal. The dollar amounts are modest individually, but the unanimity speaks loudly. Every executive with insight into Travere's pipeline, commercialization, finances, and operations made the same decision: sell now.